Navigation Links
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication
Date:12/29/2010

to bloody stools, severe diarrhea and frequent abdominal pain. Tiny open sores, or ulcers, form on the surface of the lining where they bleed and produce pus and mucus. Symptoms of the disease may lead to loss of appetite, subsequent weight loss, and fatigue.  UC is a chronic disease, and there is no cure.  Although progress has been made in inflammatory bowel disease (IBD) research, investigators do not know what causes this disease.

About REMICADE

REMICADE was the first anti-tumor necrosis factor (TNF)-alpha treatment to be approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology.  REMICADE has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO).  The safety and efficacy of REMICADE have been well established in clinical trials over the past 17 years and through commercial experience with more than one million patients treated worldwide.

In the U.S., REMICADE is approved for the following indications:

  • Reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA, when administered in combination with methotrexate.  
  • Reducing signs and symptoms in patients with active AS.
  • Reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active CD who have had an inadequate response to conventional therapy.  
  • Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing CD.  
  • Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal heal
    '/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
2. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
3. Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI® Label to Include Inhibition of Structural Damage in Treatment of Psoriatic Arthritis
4. Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
5. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
6. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
7. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
8. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
9. ORTHO EVRA(R) Prescribing Information Updated
10. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
11. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research ... announced the addition of the "Medical Device ... to their offering. This report analyzes ... US$ Million by the following Device Categories: Class ... areas also analyzed in the report Include - ...
(Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
(Date:4/17/2015)... 2015 Steven Rash , the CEO of ... operating subsidiary American Seed & Oil Company, presented the ... yesterday in New York City.  Mr. Rash,s presentation featured ... Seed & Oil Company has recently announced the ... Seed Foods , the EpiVape , and ...
Breaking Medicine Technology:Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3
... Silence Therapeutics plc (AIM: SLN) ("Silence" or ... patent 7,893,245, titled "Interfering RNA Molecules," by the ... issued patent, which represents a continuation of previously ... RNAi molecules with defined positional modifications including siRNA ...
... Feb. 22, 2011 Covance Inc. (NYSE: CVD ... Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 2Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 3Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 4Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2
(Date:4/17/2015)... Wholelifelifeinsurance.org has released a new blog post ... policies . , Whole life insurance can help ... families at the same time. Whole life insurance is ... customized to it the client’s needs. , Whole ... some appropriate steps.Comparing life insurance quotes is very important ...
(Date:4/17/2015)... Verndale, a Global Experience Technology Company, is ... chosen as a Boston Business Journal (BBJ) Pacesetter, ranking ... region. The BBJ’s Pacesetters represents privately held businesses that ... This is the eighth consecutive year and the ninth ... been honored with this award. , “Being honored with ...
(Date:4/17/2015)... 17, 2015 Cheapquotesautoinsurance.com has released a new ... has a salvage title . , An auto insurance ... a salvage title if the owner has paid for all ... title car is not possible, while in other states, the ... blog post provides more information on the subject. , ...
(Date:4/17/2015)... 17, 2015 Founder of the ... as a keynote speaker at the Couples Conference from ... Marriott in Manhattan Beach, CA. Tatkin’s presentation and panel ... can help couples become “secure-functioning” – a term he ... of research in neurobiology, arousal regulation, and infant attachment ...
(Date:4/17/2015)... York (PRWEB) April 17, 2015 The ... announced that Long Island eye surgeon Jeffrey L. Martin, ... Laser Cataract Surgery Skills Transfer Session being held April ... Dr. Martin is the Managing Partner of North Shore ... assist fellow ophthalmologists attending the Skills Transfer Session in ...
Breaking Medicine News(10 mins):Health News:Whole Life Insurance Policies At Affordable Prices By Comparing Quotes 2Health News:Verndale Honored as 2015 Boston Business Journal Pacesetter, Named 46th Fastest Growing Private Company 2Health News:Compare Auto Insurance Quotes for Cars With A Salvage Title! 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 3Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 2Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 3
... ... ("CTI") (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. ... the 2009 American Society of Hematology ("ASH") Annual Meeting updated results ... pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory, aggressive ...
... of Chicago have discovered a technique that is able to ... habitual snoring by screening their urine. "These findings ... test that could detect OSA in snoring children. This would ... children who snore, only about 20 to 30 percent of ...
... , OAK BROOK, Ill., Dec. 7 ... center (AMC) members for their achievements in UHC,s Supply ... are noted for modeling best practices in supply chain ... , The winners were determined using 2008 data and ...
... , , Consumers ... SILVER SPRING, Md., Dec. 6 The U.S. Food and Drug ... San Antonio Bay on or after Nov. 16 due to reports ... from this area, which is located on the Gulf of Texas. ...
... have discovered that the loss of a key segment of DNA ... to show that this kind of genetic alteration can cause obesity. ... study, led by Dr Sadaf Farooqi from the University of Cambridge ... at 300 children with severe obesity. The team scanned each ...
... find signs of feline DNA in virus , SUNDAY, Dec. 6 ... might be found in a tiger that lived thousands or millions ... virus took on a bit of a tiger,s genetic material, scientists ... to this day. That tiger, in fact, may have bitten a ...
Cached Medicine News:Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Urine test for pediatric obstructive sleep apnea possible 2Health News:Recognized Top Performers in UHC Supply Chain 2Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:AIDS May Date Back to Ancient Tiger 2
The Salt A-Peel™ microdermabrasion combines, positive air pressure, pure salt, ultrasound and the application of rich anti oxidant products to deliver a remarkable 'The Salt A-Peel' anti ageing...
... introduces the DiamondTome™ Skin Resurfacing System ... DiamondTome™ Wands, an evolution in microdermabrasion ... smoother, more youthful skin. , For ... benefits of DiamondTome's™ innovative approach to ...
... your aesthetic practice with the advantages of ... that's gentle, powerful and fast. With ever-increasing ... of IPL Skin Treatments using Photorejuvenation, the ... an indispensable tool for all aesthetic physicians, ...
Disposable. Sterile Suction Tubing....
Medicine Products: